Stonvex publishes market data and research only. Not investment advice. Not a registered investment advisor. Read disclaimer.

VRCA

Live52w high -38.3%

Annual Quarterly

Core line items from VRCA's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

Log in Get Started

Annual Quarterly

Financial statements

Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.

Entity: Verrica Pharmaceuticals Inc.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-08-10	Q2 2025 2025-06-30	Q1 2025 2025-03-31	Annual 2024 2024-12-31	Q3 2024 2024-09-30
Revenue	$6.08M	$16.14M	$3.44M	$7.57M	$7.22M
Operating Income	Not available	$-6.62M	$-8.13M	$-65.92M	$-54.51M
Net Income	Not available	$204.00K	$-9.74M	$-76.58M	$-60.38M
EPS (Diluted)	$-0.40	$-1.01	$-1.03	$-14.78	$-12.96
Total Assets	Not available	$39.11M	$42.18M	$54.13M	$32.93M
Total Liabilities	Not available	$56.59M	$60.75M	$63.99M	$66.98M
Cash & Equivalents	Not available	$15.40M	$29.59M	$46.33M	$22.96M
Free Cash Flow OCF − CapEx	Not available	$-22.72M	Not available	$-60.95M	$-44.89M
Shares Outstanding	Not available	9.25M	91.79M	9.18M	45.60M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.

Core line items from VRCA's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

52w high -38.3%

Financial statements

Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.

Entity: Verrica Pharmaceuticals Inc.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-08-10	Q2 2025 2025-06-30	Q1 2025 2025-03-31	Annual 2024 2024-12-31	Q3 2024 2024-09-30
Revenue	$6.08M	$16.14M	$3.44M	$7.57M	$7.22M
Operating Income	Not available	$-6.62M	$-8.13M	$-65.92M	$-54.51M
Net Income	Not available	$204.00K	$-9.74M	$-76.58M	$-60.38M
EPS (Diluted)	$-0.40	$-1.01	$-1.03	$-14.78	$-12.96
Total Assets	Not available	$39.11M	$42.18M	$54.13M	$32.93M
Total Liabilities	Not available	$56.59M	$60.75M	$63.99M	$66.98M
Cash & Equivalents	Not available	$15.40M	$29.59M	$46.33M	$22.96M
Free Cash Flow OCF − CapEx	Not available	$-22.72M	Not available	$-60.95M	$-44.89M
Shares Outstanding	Not available	9.25M	91.79M	9.18M	45.60M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.